For the last three days, A.I.dvisor has detected that IMRA's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong downtrend ahead for IMRA, and traders may view it as a Sell signal for the next month. Traders may consider selling the stock or exploring put options. A.I.dvisor backtested this indicator and found 159 similar cases, of which were successful. Based on this data, the odds of success are
IMRA saw its Momentum Indicator move below the 0 level on January 28, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 52 similar instances where the indicator turned negative. In of the 52 cases, the stock moved further down in the following days. The odds of a decline are at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMRA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for IMRA entered a downward trend on January 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IMRA's RSI Oscillator exited the oversold zone, of 19 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IMRA advanced for three days, in of 139 cases, the price rose further within the following month. The odds of a continued upward trend are .
IMRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
a company, which engages in the development and commercialization of novel therapeutics to treat patients suffering from hemoglobinopathies
Category Trading